Hiroyuki Aihara, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colonic Polyps | 11 | 2023 | 542 | 2.770 |
Why?
|
Colonoscopy | 22 | 2023 | 1367 | 2.710 |
Why?
|
Gastroscopy | 11 | 2024 | 207 | 2.150 |
Why?
|
Colorectal Neoplasms | 19 | 2022 | 6773 | 2.060 |
Why?
|
Gastric Mucosa | 8 | 2024 | 599 | 1.740 |
Why?
|
Dissection | 5 | 2021 | 295 | 1.490 |
Why?
|
Stomach | 10 | 2024 | 697 | 1.380 |
Why?
|
Intestinal Polyps | 4 | 2023 | 99 | 0.980 |
Why?
|
Suture Techniques | 7 | 2021 | 798 | 0.930 |
Why?
|
Sutures | 4 | 2022 | 299 | 0.920 |
Why?
|
Bariatrics | 1 | 2022 | 34 | 0.790 |
Why?
|
Capsule Endoscopy | 5 | 2015 | 125 | 0.770 |
Why?
|
Stomach Neoplasms | 4 | 2024 | 1333 | 0.670 |
Why?
|
Rectum | 2 | 2021 | 904 | 0.630 |
Why?
|
Gastroscopes | 2 | 2014 | 19 | 0.590 |
Why?
|
Clinical Competence | 8 | 2023 | 4687 | 0.590 |
Why?
|
Sigmoid Diseases | 1 | 2017 | 50 | 0.590 |
Why?
|
Adenoma | 5 | 2021 | 2174 | 0.570 |
Why?
|
Colon, Sigmoid | 1 | 2017 | 120 | 0.570 |
Why?
|
Esophageal Neoplasms | 6 | 2023 | 1582 | 0.540 |
Why?
|
Gastrostomy | 5 | 2019 | 309 | 0.530 |
Why?
|
Magnetics | 4 | 2015 | 607 | 0.520 |
Why?
|
Rectal Neoplasms | 3 | 2020 | 1203 | 0.500 |
Why?
|
Image Enhancement | 7 | 2020 | 2921 | 0.480 |
Why?
|
Curriculum | 8 | 2021 | 3604 | 0.480 |
Why?
|
Education, Distance | 1 | 2018 | 251 | 0.480 |
Why?
|
Fellowships and Scholarships | 2 | 2021 | 1076 | 0.480 |
Why?
|
Surgical Instruments | 6 | 2023 | 395 | 0.470 |
Why?
|
Japan | 6 | 2023 | 1361 | 0.460 |
Why?
|
Colon | 5 | 2023 | 1772 | 0.460 |
Why?
|
Color | 6 | 2021 | 307 | 0.450 |
Why?
|
Magnesium Sulfate | 1 | 2012 | 68 | 0.430 |
Why?
|
Gastric Fistula | 3 | 2017 | 73 | 0.420 |
Why?
|
Capillaries | 2 | 2012 | 774 | 0.420 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2014 | 224 | 0.420 |
Why?
|
Cathartics | 1 | 2012 | 125 | 0.400 |
Why?
|
Sulfates | 1 | 2012 | 390 | 0.400 |
Why?
|
Endoscopy | 5 | 2022 | 1784 | 0.390 |
Why?
|
Esophageal Achalasia | 2 | 2023 | 91 | 0.390 |
Why?
|
Natural Orifice Endoscopic Surgery | 2 | 2023 | 118 | 0.370 |
Why?
|
Intestinal Mucosa | 6 | 2022 | 3036 | 0.370 |
Why?
|
Colonoscopes | 1 | 2009 | 17 | 0.350 |
Why?
|
Colitis | 1 | 2017 | 1170 | 0.330 |
Why?
|
Adenomatous Polyps | 3 | 2021 | 107 | 0.320 |
Why?
|
Swine | 11 | 2018 | 5940 | 0.320 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2013 | 720 | 0.310 |
Why?
|
Rectal Diseases | 1 | 2009 | 143 | 0.300 |
Why?
|
Endoscopy, Gastrointestinal | 3 | 2023 | 868 | 0.300 |
Why?
|
Barrett Esophagus | 2 | 2021 | 494 | 0.300 |
Why?
|
Colonic Neoplasms | 2 | 2017 | 2538 | 0.300 |
Why?
|
Colonic Diseases | 1 | 2009 | 202 | 0.300 |
Why?
|
Portasystemic Shunt, Surgical | 2 | 2016 | 41 | 0.290 |
Why?
|
Cutaneous Fistula | 2 | 2017 | 78 | 0.290 |
Why?
|
Humans | 74 | 2024 | 744220 | 0.280 |
Why?
|
Diagnosis, Differential | 10 | 2018 | 12961 | 0.270 |
Why?
|
Phosphates | 1 | 2009 | 786 | 0.260 |
Why?
|
Gastrointestinal Tract | 2 | 2022 | 814 | 0.260 |
Why?
|
Prospective Studies | 15 | 2023 | 53280 | 0.250 |
Why?
|
Treatment Outcome | 19 | 2024 | 63119 | 0.240 |
Why?
|
Hyperthermia, Induced | 2 | 2009 | 403 | 0.240 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2011 | 1130 | 0.230 |
Why?
|
Polyethylene Glycols | 1 | 2009 | 1181 | 0.230 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2013 | 3328 | 0.220 |
Why?
|
Early Detection of Cancer | 3 | 2015 | 3086 | 0.220 |
Why?
|
Duodenal Neoplasms | 1 | 2023 | 106 | 0.220 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2003 | 85 | 0.210 |
Why?
|
Digestive System Surgical Procedures | 2 | 2023 | 576 | 0.210 |
Why?
|
Equipment Design | 5 | 2019 | 3582 | 0.210 |
Why?
|
Esophageal and Gastric Varices | 1 | 2023 | 207 | 0.200 |
Why?
|
Esophagoscopy | 3 | 2023 | 390 | 0.190 |
Why?
|
Oral Submucous Fibrosis | 1 | 2020 | 2 | 0.190 |
Why?
|
Multicenter Studies as Topic | 2 | 2023 | 1677 | 0.190 |
Why?
|
Peritonitis | 1 | 2003 | 365 | 0.190 |
Why?
|
Bites and Stings | 1 | 2001 | 91 | 0.190 |
Why?
|
Retrospective Studies | 19 | 2024 | 77426 | 0.180 |
Why?
|
Nephritis, Interstitial | 1 | 2001 | 156 | 0.180 |
Why?
|
Cats | 1 | 2001 | 998 | 0.180 |
Why?
|
Stomach Diseases | 2 | 2011 | 134 | 0.180 |
Why?
|
Hepatic Veins | 2 | 2016 | 112 | 0.170 |
Why?
|
Adenocarcinoma | 3 | 2021 | 6352 | 0.170 |
Why?
|
Feasibility Studies | 8 | 2023 | 5076 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2022 | 9230 | 0.160 |
Why?
|
Asia | 1 | 2020 | 610 | 0.160 |
Why?
|
Hemostasis, Surgical | 1 | 2018 | 128 | 0.160 |
Why?
|
Middle Aged | 24 | 2021 | 213367 | 0.150 |
Why?
|
Length of Stay | 2 | 2019 | 6308 | 0.150 |
Why?
|
United States | 8 | 2023 | 69867 | 0.150 |
Why?
|
Task Performance and Analysis | 2 | 2018 | 780 | 0.150 |
Why?
|
Female | 33 | 2023 | 380197 | 0.140 |
Why?
|
Models, Anatomic | 3 | 2016 | 690 | 0.140 |
Why?
|
Anal Canal | 1 | 2019 | 376 | 0.140 |
Why?
|
Endosonography | 4 | 2016 | 610 | 0.140 |
Why?
|
Jejunoileal Bypass | 1 | 2016 | 12 | 0.140 |
Why?
|
Gastric Bypass | 2 | 2015 | 812 | 0.140 |
Why?
|
Laparoscopy | 3 | 2017 | 2149 | 0.140 |
Why?
|
Capsule Endoscopes | 2 | 2015 | 16 | 0.140 |
Why?
|
Postoperative Care | 1 | 2003 | 1485 | 0.140 |
Why?
|
Biopsy | 3 | 2017 | 6757 | 0.130 |
Why?
|
Pharyngeal Neoplasms | 1 | 2016 | 117 | 0.130 |
Why?
|
Male | 29 | 2023 | 350027 | 0.130 |
Why?
|
Eating | 1 | 2003 | 1538 | 0.130 |
Why?
|
Hyperplasia | 3 | 2013 | 1184 | 0.130 |
Why?
|
Endoscopy, Digestive System | 1 | 2018 | 345 | 0.130 |
Why?
|
Sensitivity and Specificity | 4 | 2021 | 14726 | 0.130 |
Why?
|
Educational Measurement | 2 | 2018 | 1209 | 0.120 |
Why?
|
Pilot Projects | 6 | 2019 | 8321 | 0.120 |
Why?
|
Ki-67 Antigen | 2 | 2013 | 644 | 0.120 |
Why?
|
Dilatation, Pathologic | 1 | 2015 | 520 | 0.120 |
Why?
|
Aged | 20 | 2023 | 163253 | 0.120 |
Why?
|
Esophagogastric Junction | 1 | 2016 | 313 | 0.120 |
Why?
|
Precancerous Conditions | 1 | 2021 | 975 | 0.120 |
Why?
|
Comparative Effectiveness Research | 1 | 2019 | 681 | 0.120 |
Why?
|
Jejunum | 1 | 2016 | 480 | 0.120 |
Why?
|
Stents | 3 | 2021 | 3280 | 0.120 |
Why?
|
Portal Vein | 1 | 2016 | 437 | 0.120 |
Why?
|
Genes, APC | 1 | 2014 | 159 | 0.110 |
Why?
|
Ileum | 1 | 2016 | 565 | 0.110 |
Why?
|
Pharynx | 1 | 2016 | 413 | 0.110 |
Why?
|
Tumor Burden | 1 | 2019 | 1914 | 0.110 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2021 | 989 | 0.110 |
Why?
|
Predictive Value of Tests | 5 | 2015 | 15070 | 0.110 |
Why?
|
Software Design | 1 | 2013 | 176 | 0.110 |
Why?
|
Education, Medical, Continuing | 1 | 2018 | 840 | 0.110 |
Why?
|
Anastomosis, Surgical | 1 | 2016 | 987 | 0.110 |
Why?
|
Anticarcinogenic Agents | 1 | 2014 | 253 | 0.100 |
Why?
|
Proctocolectomy, Restorative | 1 | 2014 | 189 | 0.100 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2014 | 504 | 0.100 |
Why?
|
Computer Systems | 1 | 2013 | 483 | 0.100 |
Why?
|
Postoperative Complications | 3 | 2019 | 15294 | 0.090 |
Why?
|
Light | 2 | 2021 | 1374 | 0.090 |
Why?
|
Sus scrofa | 3 | 2016 | 437 | 0.090 |
Why?
|
Omentum | 1 | 2011 | 170 | 0.090 |
Why?
|
Esophagus | 1 | 2016 | 1018 | 0.090 |
Why?
|
Animals | 13 | 2018 | 168788 | 0.090 |
Why?
|
Education, Medical, Graduate | 2 | 2021 | 2291 | 0.090 |
Why?
|
Breast Neoplasms | 1 | 2017 | 20817 | 0.090 |
Why?
|
Lipectomy | 1 | 2011 | 118 | 0.090 |
Why?
|
Program Evaluation | 1 | 2018 | 2486 | 0.090 |
Why?
|
Health Care Costs | 1 | 2003 | 3209 | 0.090 |
Why?
|
Cellulose | 1 | 2009 | 123 | 0.080 |
Why?
|
Tablets | 1 | 2009 | 147 | 0.080 |
Why?
|
Ultrasonic Therapy | 1 | 2011 | 235 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2016 | 4033 | 0.080 |
Why?
|
Laxatives | 1 | 2009 | 87 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2001 | 1971 | 0.080 |
Why?
|
Colitis, Ulcerative | 1 | 2020 | 1912 | 0.080 |
Why?
|
Ultrasonography, Interventional | 1 | 2016 | 1483 | 0.080 |
Why?
|
Therapeutic Irrigation | 1 | 2009 | 301 | 0.080 |
Why?
|
Carcinoma in Situ | 1 | 2013 | 805 | 0.070 |
Why?
|
Models, Animal | 1 | 2014 | 2171 | 0.070 |
Why?
|
Drug Combinations | 1 | 2012 | 1962 | 0.070 |
Why?
|
Sepsis | 1 | 2001 | 2593 | 0.070 |
Why?
|
Sodium Chloride | 1 | 2009 | 625 | 0.070 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 972 | 0.070 |
Why?
|
Fluorescence | 1 | 2009 | 751 | 0.070 |
Why?
|
Germ-Line Mutation | 1 | 2014 | 1787 | 0.070 |
Why?
|
Reoperation | 1 | 2015 | 4203 | 0.070 |
Why?
|
Intra-Abdominal Fat | 1 | 2011 | 591 | 0.070 |
Why?
|
Internet | 1 | 2018 | 3063 | 0.070 |
Why?
|
Time Factors | 6 | 2017 | 40063 | 0.070 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 4929 | 0.060 |
Why?
|
Video Recording | 1 | 2009 | 947 | 0.060 |
Why?
|
Internship and Residency | 2 | 2021 | 5787 | 0.060 |
Why?
|
Esophageal Sphincter, Lower | 1 | 2023 | 20 | 0.060 |
Why?
|
Population Surveillance | 1 | 2014 | 2616 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2013 | 2948 | 0.050 |
Why?
|
Prognosis | 3 | 2019 | 29050 | 0.050 |
Why?
|
Sclerosis | 1 | 2003 | 213 | 0.050 |
Why?
|
Pancreas | 1 | 2009 | 1686 | 0.050 |
Why?
|
Mitomycin | 1 | 2003 | 259 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 11493 | 0.050 |
Why?
|
Intestines | 1 | 2011 | 1924 | 0.050 |
Why?
|
Carcinoma | 1 | 2013 | 2375 | 0.050 |
Why?
|
Adult | 11 | 2017 | 214035 | 0.050 |
Why?
|
Genetic Testing | 1 | 2014 | 3443 | 0.050 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2001 | 188 | 0.050 |
Why?
|
Lifting | 1 | 2020 | 56 | 0.050 |
Why?
|
Patient Satisfaction | 1 | 2012 | 3395 | 0.040 |
Why?
|
Neoplasm Invasiveness | 3 | 2014 | 3614 | 0.040 |
Why?
|
Traction | 1 | 2019 | 106 | 0.040 |
Why?
|
Postoperative Hemorrhage | 1 | 2023 | 412 | 0.040 |
Why?
|
Intestinal Obstruction | 1 | 2003 | 424 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2023 | 19907 | 0.040 |
Why?
|
Endoscopes, Gastrointestinal | 1 | 2018 | 60 | 0.040 |
Why?
|
Granuloma | 1 | 2020 | 317 | 0.040 |
Why?
|
Fluorouracil | 1 | 2003 | 1616 | 0.040 |
Why?
|
Brazil | 1 | 2022 | 1270 | 0.040 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 2017 | 87 | 0.040 |
Why?
|
Tensile Strength | 1 | 2018 | 335 | 0.040 |
Why?
|
Cisplatin | 1 | 2003 | 1642 | 0.040 |
Why?
|
Portal Pressure | 1 | 2016 | 62 | 0.040 |
Why?
|
Methotrexate | 1 | 2003 | 1720 | 0.030 |
Why?
|
Postoperative Period | 1 | 2021 | 1841 | 0.030 |
Why?
|
Gastrointestinal Agents | 1 | 2020 | 494 | 0.030 |
Why?
|
Surgical Stapling | 1 | 2016 | 97 | 0.030 |
Why?
|
Canada | 1 | 2021 | 2065 | 0.030 |
Why?
|
Learning Curve | 1 | 2017 | 208 | 0.030 |
Why?
|
Observer Variation | 1 | 2021 | 2593 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18027 | 0.030 |
Why?
|
Gastric Stump | 1 | 2014 | 8 | 0.030 |
Why?
|
Materials Testing | 1 | 2018 | 867 | 0.030 |
Why?
|
Shock, Septic | 1 | 2001 | 775 | 0.030 |
Why?
|
Employment | 1 | 2021 | 1129 | 0.030 |
Why?
|
Neoplasm Staging | 3 | 2016 | 11007 | 0.030 |
Why?
|
Iodides | 1 | 2013 | 41 | 0.030 |
Why?
|
Cohort Studies | 3 | 2023 | 40559 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2023 | 1864 | 0.030 |
Why?
|
Pressure | 1 | 2016 | 1203 | 0.030 |
Why?
|
Risk Factors | 1 | 2019 | 72280 | 0.030 |
Why?
|
Peritoneal Cavity | 1 | 2011 | 148 | 0.020 |
Why?
|
Teaching | 1 | 2018 | 1174 | 0.020 |
Why?
|
Coloring Agents | 1 | 2013 | 566 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 1789 | 0.020 |
Why?
|
Workload | 1 | 2016 | 850 | 0.020 |
Why?
|
Patient Discharge | 1 | 2023 | 3313 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2013 | 11368 | 0.020 |
Why?
|
Area Under Curve | 1 | 2013 | 1655 | 0.020 |
Why?
|
Mutation | 1 | 2014 | 29784 | 0.020 |
Why?
|
Injections, Intralesional | 1 | 2009 | 276 | 0.020 |
Why?
|
Surgery, Computer-Assisted | 1 | 2016 | 1018 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2011 | 1590 | 0.020 |
Why?
|
Patient Preference | 1 | 2015 | 887 | 0.020 |
Why?
|
Ultrasonography | 1 | 2020 | 5982 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3509 | 0.020 |
Why?
|
Wound Healing | 1 | 2017 | 2785 | 0.020 |
Why?
|
Bariatric Surgery | 1 | 2015 | 952 | 0.020 |
Why?
|
ROC Curve | 1 | 2013 | 3527 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2011 | 1062 | 0.020 |
Why?
|
Necrosis | 1 | 2009 | 1643 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2013 | 6367 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2016 | 57768 | 0.020 |
Why?
|
Gastroesophageal Reflux | 1 | 2011 | 782 | 0.020 |
Why?
|
Computer Simulation | 1 | 2017 | 6196 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2007 | 1770 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2015 | 39045 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2011 | 8628 | 0.010 |
Why?
|
Radiation Dosage | 1 | 2007 | 1928 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2013 | 10480 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2007 | 4841 | 0.010 |
Why?
|
Survival Rate | 1 | 2011 | 12781 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2007 | 6535 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2007 | 2726 | 0.010 |
Why?
|
Young Adult | 2 | 2011 | 56436 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13280 | 0.010 |
Why?
|
Algorithms | 1 | 2013 | 13885 | 0.010 |
Why?
|
Risk Assessment | 1 | 2007 | 23337 | 0.000 |
Why?
|